{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:26:50Z","timestamp":1791379610661,"version":"4.3.3"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100006034","name":"University of Southern California","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006034","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajo.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.ajo.2025.12.003","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:36:23Z","timestamp":1765006583000},"page":"120-128","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes"],"prefix":"10.1016","volume":"283","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8689-6391","authenticated-orcid":false,"given":"Alexander T.","family":"Hong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4448-678X","authenticated-orcid":false,"given":"Forest","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5271-7690","authenticated-orcid":false,"given":"Sally","family":"Baxter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-3202","authenticated-orcid":false,"given":"Robert N.","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.ajo.2025.12.003_bib0001","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","article-title":"Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis","volume":"121","author":"Tham","year":"2014","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.003_bib0002","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1016\/S2214-109X(17)30393-5","article-title":"Global causes of blindness and distance vision impairment 1990\u20132020: a systematic review and meta-analysis","volume":"5","author":"Flaxman","year":"2017","journal-title":"Lancet Glob Health"},{"issue":"10414","key":"10.1016\/j.ajo.2025.12.003_bib0003","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1016\/S0140-6736(23)01289-8","article-title":"Glaucoma: now and beyond","volume":"402","author":"Jayaram","year":"2023","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ajo.2025.12.003_bib0004","first-page":"224","article-title":"Oxygen and blood flow: players in the pathogenesis of glaucoma","volume":"14","author":"Mozaffarieh","year":"2008","journal-title":"Mol Vis"},{"key":"10.1016\/j.ajo.2025.12.003_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.preteyeres.2020.100916","article-title":"Inflammation in glaucoma: from the back to the front of the eye, and beyond","volume":"83","author":"Baudouin","year":"2021","journal-title":"Prog Retin Eye Res"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.003_bib0006","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/j.ophtha.2007.04.049","article-title":"Type 2 diabetes mellitus and the risk of open-angle glaucoma the Los Angeles Latino Eye Study","volume":"115","author":"Chopra","year":"2008","journal-title":"Ophthalmology"},{"issue":"8","key":"10.1016\/j.ajo.2025.12.003_bib0007","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0102972","article-title":"Diabetes mellitus as a risk factor for open-angle glaucoma: a systematic review and meta-analysis","volume":"9","author":"Zhou","year":"2014","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.ajo.2025.12.003_bib0008","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1007\/s11892-016-0815-6","article-title":"Presence and risk factors for glaucoma in patients with diabetes","volume":"16","author":"Song","year":"2016","journal-title":"Curr Diab Rep"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.003_bib0009","doi-asserted-by":"crossref","first-page":"676","DOI":"10.3390\/jcm13030676","article-title":"Factors associated with increased intraocular pressure in type 2 diabetes patients","volume":"13","author":"Braha","year":"2024","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.003_bib0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.108271","article-title":"GLP-1 receptor agonist NLY01 reduces retinal inflammation and neuron death secondary to ocular hypertension","volume":"33","author":"Sterling","year":"2020","journal-title":"Cell Rep"},{"key":"10.1016\/j.ajo.2025.12.003_bib0011","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2023.1156829","article-title":"Topical and systemic GLP-1R agonist administration both rescue retinal ganglion cells in hypertensive glaucoma","volume":"17","author":"Lawrence","year":"2023","journal-title":"Front Cell Neurosci"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.003_bib0012","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/bph.15683","article-title":"The role of glia in the physiology and pharmacology of glucagon-like peptide-1: implications for obesity, diabetes, neurodegeneration and glaucoma","volume":"179","author":"Cui","year":"2022","journal-title":"Br J Pharmacol"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.003_bib0013","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1136\/bjophthalmol-2021-319232","article-title":"Glucagon-like peptide 1 receptor agonist use is associated with reduced risk for glaucoma","volume":"107","author":"Sterling","year":"2023","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.003_bib0014","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.ophtha.2024.08.023","article-title":"Comparative effects of glucagon-like peptide 1 receptor agonists and metformin on glaucoma risk in patients with type 2 diabetes","volume":"132","author":"Muayad","year":"2025","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ajo.2025.12.003_bib0015","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ajo.2024.08.030","article-title":"Association between glucagon-like peptide-1 receptor agonists exposure and intraocular pressure change: GLP-1 receptor agonists and intraocular pressure change","volume":"269","author":"Hallaj","year":"2025","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.003_bib0016","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ophtha.2024.03.004","article-title":"Association between glucagon-like peptide-1 receptor agonists and the risk of glaucoma in individuals with type 2 diabetes","volume":"131","author":"Niazi","year":"2024","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.003_bib0017","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa2107519","article-title":"Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes","volume":"385","author":"Fr\u00edas","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.ajo.2025.12.003_bib0018","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1056\/NEJMoa2206038","article-title":"Tirzepatide once weekly for the treatment of obesity","volume":"387","author":"Jastreboff","year":"2022","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ajo.2025.12.003_bib0019","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1056\/NEJMoa2410819","article-title":"Tirzepatide for obesity treatment and diabetes prevention","volume":"392","author":"Jastreboff","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.003_bib0020","doi-asserted-by":"crossref","first-page":"ooad035","DOI":"10.1093\/jamiaopen\/ooad035","article-title":"A global federated real-world data and analytics platform for research","volume":"6","author":"Palchuk","year":"2023","journal-title":"JAMIA Open"},{"issue":"7624","key":"10.1016\/j.ajo.2025.12.003_bib0021","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1136\/bmj.39335.541782.AD","article-title":"Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"335","author":"von Elm","year":"2007","journal-title":"BMJ"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.003_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.14831","article-title":"Tirzepatide for the treatment of adults with type 2 diabetes: an endocrine perspective","volume":"25","author":"De Block","year":"2023","journal-title":"Diabetes Obes Metab"},{"issue":"10295","key":"10.1016\/j.ajo.2025.12.003_bib0023","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(21)01324-6","article-title":"Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial","volume":"398","author":"Rosenstock","year":"2021","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.ajo.2025.12.003_bib0024","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2024.102777","article-title":"Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study","volume":"75","author":"Anson","year":"2024","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.ajo.2025.12.003_bib0025","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2023.102967","article-title":"Oxidative stress in the eye and its role in the pathophysiology of ocular diseases","volume":"68","author":"B\u00f6hm","year":"2023","journal-title":"Redox Biol"},{"key":"10.1016\/j.ajo.2025.12.003_bib0026","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ajo.2018.06.021","article-title":"Systemic disease and long-term intraocular pressure mean, peak, and variability in nonglaucomatous eyes","volume":"193","author":"Dikopf","year":"2018","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"10.1016\/j.ajo.2025.12.003_bib0027","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1167\/iovs.15-18373","article-title":"Diabetes, triglyceride levels, and other risk factors for glaucoma in the National Health and Nutrition Examination Survey 2005-2008","volume":"57","author":"Ko","year":"2016","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.003_bib0028","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1167\/iovs.62.9.9","article-title":"Diabetes exacerbates the intraocular pressure-independent retinal ganglion cells degeneration in the DBA\/2J model of Glaucoma","volume":"62","author":"Amato","year":"2021","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.003_bib0029","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1136\/bjophthalmol-2018-312568","article-title":"United Kingdom Diabetic Retinopathy Electronic Medical Record (UK DR EMR) users group: report 4, real-world data on the impact of deprivation on the presentation of diabetic eye disease at hospital services","volume":"103","author":"Denniston","year":"2019","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"10.1016\/j.ajo.2025.12.003_bib0030","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1111\/dom.15865","article-title":"Association of glycaemic control with intraocular pressure in a large general population: results from the UK Biobank","volume":"26","author":"Liu","year":"2024","journal-title":"Diabetes Obes Metab"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.003_bib0031","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3390\/jcm12052066","article-title":"Metabolic health, obesity, and intraocular pressure","volume":"12","author":"Jung","year":"2023","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.003_bib0032","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1016\/j.ophtha.2022.04.023","article-title":"The association between serum lipids and intraocular pressure in 2 large United Kingdom cohorts","volume":"129","author":"Madjedi","year":"2022","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.003_bib0033","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234042","article-title":"Systemic factors associated with intraocular pressure among subjects in a health examination program in Japan","volume":"15","author":"Takahashi","year":"2020","journal-title":"PLoS ONE"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.003_bib0034","doi-asserted-by":"crossref","first-page":"872","DOI":"10.3390\/biom14070872","article-title":"Incretin-based multi-agonist peptides are neuroprotective and anti-inflammatory in cellular models of neurodegeneration","volume":"14","author":"Kopp","year":"2024","journal-title":"Biomolecules"},{"key":"10.1016\/j.ajo.2025.12.003_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2020.117824","article-title":"Neuroprotection of GLP-1\/GIP receptor agonist via inhibition of mitochondrial stress by AKT\/JNK pathway in a Parkinson\u2019s disease model","volume":"256","author":"Li","year":"2020","journal-title":"Life Sci"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.003_bib0036","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12967-024-04927-z","article-title":"Tirzepatide prevents neurodegeneration through multiple molecular pathways","volume":"22","author":"Fontanella","year":"2024","journal-title":"J Transl Med"},{"key":"10.1016\/j.ajo.2025.12.003_bib0037","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170194","article-title":"The glucose-dependent insulinotropic polypeptide signaling axis in the central nervous system","volume":"125","author":"Adriaenssens","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.ajo.2025.12.003_bib0038","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2022.170749","article-title":"GLP-1 and GIP receptor signaling in beta cells\u2014a review of receptor interactions and co-stimulation","volume":"151","author":"Mayendraraj","year":"2022","journal-title":"Peptides"},{"key":"10.1016\/j.ajo.2025.12.003_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2019.107813","article-title":"Neuroprotective and restorative properties of the GLP-1\/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer\u2019s disease","volume":"162","author":"Salles","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.ajo.2025.12.003_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170184","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson\u2019s disease models","volume":"125","author":"Zhang","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.ajo.2025.12.003_bib0041","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1415521","article-title":"Insulin resistance in the retina: possible implications for certain ocular diseases","volume":"15","author":"Zheng","year":"2024","journal-title":"Front Endocrinol"},{"issue":"9","key":"10.1016\/j.ajo.2025.12.003_bib0042","doi-asserted-by":"crossref","first-page":"4672","DOI":"10.3390\/ijms22094672","article-title":"Insulin signaling as a therapeutic target in glaucomatous neurodegeneration","volume":"22","author":"Al Hussein Al Awamlh","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.ajo.2025.12.003_bib0043","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1016\/j.cmet.2024.05.010","article-title":"Tirzepatide modulates the regulation of adipocyte nutrient metabolism through long-acting activation of the GIP receptor","volume":"36","author":"Regmi","year":"2024","journal-title":"Cell Metab"},{"issue":"suppl_1","key":"10.1016\/j.ajo.2025.12.003_bib0044","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.2337\/db19-1009-P","article-title":"1009-P: the dual GIP and GLP-1 receptor agonist tirzepatide regulates lipid and carbohydrate metabolism through GIPR in adipose tissue","volume":"68","author":"Samms","year":"2019","journal-title":"Diabetes"},{"issue":"17","key":"10.1016\/j.ajo.2025.12.003_bib0045","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.140532","article-title":"Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist","volume":"5","author":"Willard","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.ajo.2025.12.003_bib0046","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171117","article-title":"The dual incretin co-agonist tirzepatide increases both insulin secretion and glucose effectiveness in model experiments in mice","volume":"171","author":"Pacini","year":"2024","journal-title":"Peptides"},{"issue":"6","key":"10.1016\/j.ajo.2025.12.003_bib0047","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1080\/02699052.2019.1587000","article-title":"GLP-1\u2019s role in neuroprotection: a systematic review","volume":"33","author":"Erbil","year":"2019","journal-title":"Brain Inj"},{"key":"10.1016\/j.ajo.2025.12.003_bib0048","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer\u2019s and Parkinson\u2019s disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front Neurosci"},{"issue":"1","key":"10.1016\/j.ajo.2025.12.003_bib0049","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.57349","article-title":"Discontinuation and reinitiation of dual-labeled GLP-1 receptor agonists among US adults with overweight or obesity","volume":"8","author":"Rodriguez","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"18","key":"10.1016\/j.ajo.2025.12.003_bib0050","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.ajo.2025.12.003_bib0051","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.13172","article-title":"GLP-1 receptor agonist discontinuation among patients with obesity and\/or type 2 diabetes","volume":"7","author":"Do","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.ajo.2025.12.003_bib0052","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/dom.15333","article-title":"Gastrointestinal adverse events and weight reduction in people with type 2 diabetes treated with tirzepatide in the SURPASS clinical trials","volume":"26","author":"Patel","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.ajo.2025.12.003_bib0053","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101364","article-title":"Associations of statin use with the onset and progression of open-angle glaucoma: a systematic review and meta-analysis","volume":"46","author":"Yuan","year":"2022","journal-title":"EClinicalMedicine"}],"container-title":["American Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006531?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002939425006531?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T13:13:09Z","timestamp":1781788389000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002939425006531"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":53,"alternative-id":["S0002939425006531"],"URL":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.003","relation":{},"ISSN":["0002-9394"],"issn-type":[{"value":"0002-9394","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tirzepatide is Associated With Reduced Risk of Primary Open-Angle Glaucoma and Ocular Hypertension in Patients With Type 2 Diabetes","name":"articletitle","label":"Article Title"},{"value":"American Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajo.2025.12.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}